Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM671NG)

• Drug Name: Progabide Drug Info
• Synonyms: Gabren; Gabrene; Halogabide; Progabida; Progabidum; SL 76002; Gabren (TN); Gabrene (TN); Progabida [INN-Spanish]; Progabidum [INN-Latin]; SL 76-002; SL-76002; Progabide (USAN/INN); Progabide [USAN:BAN:INN]; Progabide [USAN:INN:BAN]; 4-(((4-Chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)butanamide; 4-((alpha-(p-Chlorophenyl)-5-fluorosalicylidene)amino)butyramide; 4-(alpha-(p-Chlorophenyl)-5-fluoro-2-hydroxybenzylideneamino)butyramide; 4-[[(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; 4-[[(E)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide; 4-[[(Z)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]

• Therapeutic Class: Antidepressants
• Cross-matching ID:
  PubChem CID: 44115
  ChEBI ID: CHEBI:135422
  CAS Number: CAS 62666-20-0
  TTD Drug ID: DM671NG

Molecule-Related Drug Atlas

Drug(s) Targeting Gamma-aminobutyric acid B receptor (GABBR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[3]
Gamma Hydroxybutyric Acid	DMGBKVD	Narcolepsy	7A20	Approved	[4]
Baclofen	DM0QV1J	Multiple sclerosis	8A40	Approved	[5]
Arbaclofen placarbil	DMO628K	Fragile X syndrome	LD55	Phase 3	[6]
[3H](R)-(-)-baclofen	DMLRHM5	Multiple sclerosis	8A40	Phase 3	[7]
Arabaclofen	DMZB9RI	Fragile X syndrome	LD55	Phase 3	[8]
GSK683699	DMTW79H	Inflammatory bowel disease	DD72	Phase 2	[9]
SGS742	DM5XYFH	Schizophrenia	6A20	Phase 2	[10]
SSTarbaclofen	DMRGTZ2	Autism spectrum disorder	6A02	Phase 2	[11]
ASP8062	DMR1MIV	Fibromyalgia	MG30.01	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gamma-aminobutyric acid B receptor (GABBR)	TTDCVZW	GABR1_HUMAN; GABR2_HUMAN	Agonist	[2]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47.
• [3] Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9.
• [6] Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242).
• [8] Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84.
• [9] 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60.
• [10] SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87.
• [11] Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)